← Back to Analyst Consensus 
ATTO Buy
Attovia Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 11
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Aug 31, 2026 | Citigroup | initiate | — → Buy | — | 54% |
| Aug 31, 2026 | LifeSci Capital | initiate | — → Outperform | — | 57% |
| Aug 31, 2026 | Leerink Partners | initiate | — → Outperform | — | 51% |
| Aug 31, 2026 | RBC Capital | initiate | — → Outperform | — | 55% |
| Aug 31, 2026 | Morgan Stanley | initiate | — → Overweight | — | 54% |
Price Target Trend
Sep 2, 2026 Latest: $42.2 Oct 24, 2026
EPS Estimates
0y $-3.45
Lo: $-3.45 Hi: $-3.45
1 analysts +1q $-0.52
Lo: $-0.52 Hi: $-0.52
1 analysts +1y $-2.38
Lo: $-2.38 Hi: $-2.38
1 analysts 0q $-0.50
Lo: $-0.50 Hi: $-0.50
1 analysts Cross-Platform Signals
No cross-platform signals in the last 90 days